A new GLP-1 pill melted away the pounds. Is Structure Therapeutics a takeover candidate?

Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, ...

Structure Weight-Loss Pill Results Rival Novo, Lilly Treatments

Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping ...
BioSpace

Structure Climbs on ‘Highly Competitive’ Profile for Weight Loss Pill

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.
Fierce Biotech

Structure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yet

“The consistent weight loss observed across multiple studies to date reaffirms aleniglipron’s potential to be a best-in-class oral GLP-1, with injectable-like efficacy that could become a backbone ...

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...
Blockonomi

Structure Therapeutics (GPCR) Stock Jumps 10% After Breakthrough GLP-1 Weight Loss Data

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.
BioPharma Dive

Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which regulators could approve within weeks.